(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Massive supernova explosion may have created a binary black hole - 2Countdown to Artemis II: What to know about NASA's moon mission
- 3Famous Network programs in Europe and America
- 4Ministry: New German petrol price regulation takes effect on April 1
- 5We may have less control over how long we live than previously thought
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- Figure out How to Adjust Your Handshake to Various Societies
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- Vote In favor of Your Favored Kind Of Cheddar
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- The Significance of a Land Lawyer for Your Business
- The Best Web-based Courses for Ability Advancement
